Abstract
Purpose. A highly lipophilic antitumor agent, 13-O-palmitoyl-rhizoxin (RS-1541), was incorporated into lipid emulsions of various sizes consisting of triglyceride ODO and surfactant HCO-60. Pharmacokinetics, toxicities, and antitumor activities were evaluated after intravenous administration to mice bearing subcutaneously inoculated M5076 sarcoma cells.
Methods. The levels of RS-1541 in the plasma and tissues including tumor, were determined by HPLC. The maximum tolerated dose (MTD) was estimated by toxic death and change in body weight. The decrease in tumor diameter was measured for antitumor activity.
Results. There existed large variations in pharmacokinetics of RS-1541, depending on the size of emulsion particles. Compared with a colloidal solution (reference solution), the small (110nm) and medium (230nm) size emulsions showed high concentrations of RS-1541 in the tumor, while the large emulsions (350nm–630nm) exhibited low concentrations. The MTD of RS-1541 was reduced, when incorporated in the emulsions larger than 220nm in size. At MTD, each size of emulsions (70nm–380nm) effectively retarded the tumor growth and increased survival time. The maximum effect was achieved for the 220 nm emulsions.
Conclusions. When particle size is properly selected, these emulsions could be promising and effective as an injectable carrier for lipophilic antitumor agents in order to enhance the tumor delivery and efficacies while reducing toxicities.
Similar content being viewed by others
REFERENCES
M. Takahashi, S. Iwasaki, H. Kobayashi, S. Okuda, T. Murai, and Y. Sato. Rhizoxin binding to tubulin at the maytansine-binding site. Biochim. Biophys. Acta 926:215–223 (1987).
T. Kobayashi, K. Sasagawa, K. Hirai, T. Nishimura, T. Tsuruo, S. Iwasaki, S. Tsukagoshi, and S. Okuda. Antitumor activities of new antitumor antibiotic derivatives, acylated rhizoxins. In Abstracts of the 16th International Congress of Chemotherapy, Jerusalem, Israel, 1989, pp. 739. 1–2.
D. D. Lasic, F. J. Martin, A. Gabizon, S. K. Huang, and D. Papahadjopoulos. Sterically stabilized liposome: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070:187–192 (1991).
A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, K. Sasagawa, T. Kobayashi, and M. Hisaoka. Lipid emulsions of palmitoyl rhizoxin: effects of composition on lipolysis and biodistribution. Biopharm. Drug Disposit. (in press)
A. Kurihara, Y. Shibayama, A. Yasuno, M. Ikeda, and M. Hisaoka. Lipid emulsions of palmitoyl rhizoxin: Effects of particle size on blood dispositions of emulsion lipid and incorporated compound in rats. Biopharm. Drug Disposit. (in press)
A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, and M. Hisaoka. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol.Pharm.Bull. (in press)
K. Y. Robert, Z. Cheng, and C. C. Cheng. Delivery of anticancer drugs. Meth. and Find. Exp. Clin. Pharmacol. 11:439–529 (1989).
R. Perez-Soler, and W. Priebe, W. Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemother. Pharmacol. 30:267–271 (1992).
P. Couvreur, L. Roblot-Treupel, M. F. Poupon, F. Brasseur, and F. Puisieux. Nanoparticles as microcarriers for anticancer drugs. Adv. Drug Del. Rev. 5:209–230 (1990).
L. C. Collins-Gold, R. T. Lyons, and L. C. Bartholow. Parenteral emulsions for drug delivery. Adv. Drug Del. Rev. 5:189–208 (1990).
T. Tanaka, Y. Kaneo, S. Shiramoto, and S. Iguchi. The dispositions of serum proteins as drug-carriers in mice bearing sarcoma 180. Biol. Pharm. Bull. 16:1270–1275 (1993).
A. Gabizon and D. Papahadjopoulos. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85:6949–6953 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kurihara, A., Shibayama, Y., Mizota, A. et al. Enhanced Tumor Delivery and Antitumor Activity of Palmitoyl Rhizoxin Using Stable Lipid Emulsions in Mice. Pharm Res 13, 305–310 (1996). https://doi.org/10.1023/A:1016063719541
Issue Date:
DOI: https://doi.org/10.1023/A:1016063719541